Hover to zoom
GLP-1 & MetabolicSynthetic triple-agonist peptide (GLP-1 / GIP / glucagon)
Retatrutide
$59.99
10 mg· 4 strengths availableRetatrutide is a synthetic peptide investigated as a triple receptor agonist, with reported activity at the GIP, GLP-1, and glucagon receptors.
It is studied as a laboratory tool for examining how simultaneous activation of three related metabolic receptors differs from single- or dual-receptor agonism. Characterization of the compound is comparatively recent, so much of its profile remains an active area of preclinical investigation.
Research areas
Triple receptor agonismGlucagon receptor signalingIncretin biologyPreclinical research
Form: Lyophilized (freeze-dried)
- Compound class
- Synthetic triple-agonist peptide (GLP-1 / GIP / glucagon)
- Research category
- GLP-1 & Metabolic
- SKU
- NVR-RETATRUTIDE-10MG
- Alternate name
- Reta
- CAS
- 2381089-83-2
- Appearance
- White to off-white lyophilized powder
- Storage
- Store lyophilized at −20 °C. Protect from light and moisture.
Research use only
Select strength
Cost per mg shown for each option
1
$59.99per 10 mg$6.00/mg
For research use only — not for human or animal consumption.
Supplied solely for legitimate laboratory and research purposes. Not for medical or veterinary use, diagnosis, treatment, or prevention of disease.
Research Grade
Batch Documentation
Research Use Only
U.S.-Based Fulfillment
What you should know
More detail on Retatrutide.
Analytical values reflect per-lot documentation and appear once a batch is released.
Compound
Retatrutide extends the multi-agonist approach seen in dual incretin peptides by adding glucagon-receptor activity. Glucagon receptor signaling engages hepatic pathways that are distinct from the islet-focused pathways associated with GIP and GLP-1, so combined agonism gives researchers a single molecule for probing several arms of metabolic regulation at once. Laboratory work typically focuses on comparative receptor potency, cyclic-AMP response profiles, and how the three activities interact in preclinical models. Because the published literature is still developing, findings should be treated as preliminary and experimental.
Peptide class
Synthetic triple-agonist peptide (GLP-1 / GIP / glucagon)
Mechanism (research context)
As a triple agonist, retatrutide interacts with three metabolic receptor systems simultaneously in preclinical research models — a mechanism of interest to investigators studying combined incretin and glucagon-receptor pharmacology.
Why it is studied
Retatrutide is one of the most extensively cited triple-agonist research peptides in current metabolic pharmacology literature.
Current areas of research
Triple receptor agonismGlucagon receptor signalingIncretin biologyPreclinical research
Topics reflect published preclinical and in vitro research. Reference only — not a claim of clinical outcomes.
Scientific background
Retatrutide represents an evolution of incretin-analog research beyond dual agonists such as tirzepatide, adding glucagon-receptor engagement to the pharmacological profile.
It has been the subject of extensive published preclinical work and remains an actively studied research compound in metabolic pharmacology.
Related
View all →Related research materials
Cagrilintide
10 mg
Long-acting amylin analog studied for amylin and calcitonin receptor signaling in laboratory models.
$99.99
DetailsCagrilintide / Semaglutide
5/5 mg
Research blend pairing an amylin analog with a GLP-1 receptor agonist for combined-pathway studies.
$119.99
DetailsHGH Fragment 176-191
5 mg
Unmodified C-terminal growth-hormone fragment used in comparative adipose-tissue research.
$69.99
DetailsRetatrutide
10 mg · $59.99